Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen

Area of Science:

• Oncology
• Immunotherapy
• Gastroenterology

Background:

• Colorectal cancer (CRC) is a major global cause of cancer mortality.
• Current treatments like surgery and chemoradiation have limited efficacy, with 50% of patients succumbing to metastatic disease.
• Existing immunotherapies for CRC show limited success due to a lack of suitable antigen targets.

Purpose of the Study:

• To identify novel therapeutic targets for colorectal cancer immunotherapy.
• To explore the potential of cancer-mucosa antigens (CMAs) for targeted treatment.
• To evaluate Guanylyl cyclase C (GCC) as a candidate CMA for clinical application.

Main Methods:

• Investigated antigens with expression restricted to normal intestinal mucosa and colorectal tumors.
• Identified Guanylyl cyclase C (GCC) as a protein with intestine/colorectal cancer-restricted expression.
• Proposed GCC as the first CMA for clinical evaluation in immunotherapy.

Main Results:

• Discovered cancer-mucosa antigens (CMAs) as a potential class of immune targets.
• Guanylyl cyclase C (GCC) demonstrated restricted expression in the intestine and colorectal tumors.
• GCC is proposed as a suitable target for developing efficacious antitumor immunotherapy.

Conclusions:

• Exploiting immune compartmentalization via CMAs offers a novel strategy for colorectal cancer immunotherapy.
• Guanylyl cyclase C (GCC) represents a promising and clinically relevant target for targeted immunotherapeutic approaches.
• Targeting GCC may overcome limitations of current treatments and improve outcomes for metastatic colorectal cancer patients.